Abstract
Novel, non-invasive biomarkers to diagnose breast cancer with high sensitivity and specificity are greatly desired. Circulating microRNAs (miRNAs) show potential for breast cancer detection, but the existing results appear to be mixed. Using microscale serum, we established a novel serum-direct multiplex detection assay based on RT-PCR (SdM-RT-PCR). Ninety-three miRNAs dysregulated or with functions in breast cancer were selected as candidates, and additional 3 miRNAs were chosen as endogenous controls. We first conducted miRNA profiling of these 96 miRNAs by SdM-RT-PCR using the sera of 25 breast cancer patients at diagnosis prior to treatment and 20 age-matched healthy controls. miRNAs showing significantly different expression levels between patients and controls were further analyzed using a logistic regression model. A miRNA signature was validated in an independent set of 128 serum samples composed of 76 breast cancer patients and 52 healthy controls. In the discovery stage, we identified 23 miRNAs as significantly dysregulated in breast cancer patients compared with healthy controls. Of these, 10 miRNAs were previously identified as dysregulated in breast cancer; 14 miRNAs remained significant after P-values were adjusted by both correction methods. Principal component analysis and hierarchical clustering of these miRNAs separated patients from controls. Furthermore, the 3-miRNA signature (miR-199a, miR-29c, and miR-424) with the highest diagnostic accuracy for distinguishing breast cancer patients from controls by ROC curve analysis (AUC = 0.888) was successfully confirmed in the validation set (AUC = 0.901). Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank. Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
Abbreviations
- AUC:
-
Area under curve
- ER:
-
Estrogen receptor
- HER2:
-
Human epidermal factor 2
- LN:
-
Lymph node
- PR:
-
Progesterone receptor
- ROC:
-
Receiver operating characteristic
References
Bertos NR, Park M (2011) Breast cancer—one term, many entities? J Clin Invest 121(10):3789–3796
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90
Maxmen A (2012) The hard facts. Nature 485(7400):S50–S51
Mandelblatt JS, Cronin KA, Bailey S et al (2009) Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151(10):738–747
Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367(21):1998–2005
Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312
Duffy MJ, Evoy D, McDermott EW (2010) CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 411(23–24):1869–1874
Patani N, Martin LA, Dowsett M (2013) Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 133(1):1–13
Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20
Friedman RC, Farh KK, Burge CB et al (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105
Karp X, Ambros V (2005) Developmental biology. Encountering microRNAs in cell fate signaling. Science 310(5752):1288–1289
Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838
Mulrane L, McGee SF, Gallagher WM et al (2013) miRNA dysregulation in breast cancer. Cancer Res 73(22):6554–6562
Volinia S, Galasso M, Sana ME et al (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109(8):3024–3029
Andorfer CA, Necela BM, Thompson EA et al (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17(6):313–319
Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006
Lawrie CH, Gal S, Dunlop HM et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141(5):672–675
Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518
Le HB, Zhu WY, Chen DD et al (2012) Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol 29(5):3190–3197
Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32(2):326–348
Heneghan HM, Miller N, Kelly R et al (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15(7):673–682
Sun Y, Wang M, Lin G et al (2012) Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 7(10):e47003
Roth C, Rack B, Muller V et al (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12(6):R90
Asaga S, Kuo C, Nguyen T et al (2011) Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 57(1):84–91
Schwarzenbach H, Milde-Langosch K, Steinbach B et al (2012) Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 134(3):933–941
Cuk K, Zucknick M, Heil J et al (2012) Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132(7):1602–1612
Chan M, Liaw CS, Ji SM et al (2013) Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19(16):4477–4487
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11(6):426–437
Hu Z, Dong J, Wang LE et al (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33(4):828–834
Zhou J, Yu L, Gao X et al (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29(36):4781–4788
Xiang M, Zeng Y, Yang R et al (2014) U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun 454(1):210–214
Godfrey AC, Xu Z, Weinberg CR et al (2013) Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res 15(3):R42
Foekens JA, Sieuwerts AM, Smid M et al (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105(35):13021–13026
Redova M, Sana J, Slaby O (2013) Circulating miRNAs as new blood-based biomarkers for solid cancers. Futur Oncol 9(3):387–402
Hu Z, Dong J, Wang LE et al (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis
Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64(15):5245–5250
Vandesompele J, De Preter K, Pattyn F et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (7):RESEARCH0034
Wang SM, Ooi LL, Hui KM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13(21):6275–6283
Taplin S, Abraham L, Barlow WE et al (2008) Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst 100(12):876–887
Checka CM, Chun JE, Schnabel FR et al (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198(3):W292–W295
Britton P, Warwick J, Wallis MG et al (2012) Measuring the accuracy of diagnostic imaging in symptomatic breast patients: team and individual performance. Br J Radiol 85(1012):415–422
Kirschner MB, Kao SC, Edelman JJ et al (2011) Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 6(9):e24145
Witwer KW (2015) Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 61(1):56–63
Shiao SL, Ganesan AP, Rugo HS et al (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 25(24):2559–2572
Tan GW, Khoo AS, Tan LP (2015) Evaluation of extraction kits and RT-qPCR systems adapted to high-throughput platform for circulating miRNAs. Sci Rep 5:9430
Ono S, Oyama T, Lam S et al (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6(9):7053–7064
Wang Y, Gao X, Wei F et al (2014) Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 533(1):389–397
Shimono Y, Zabala M, Cho RW et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3):592–603
Yan LX, Huang XF, Shao Q et al (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11):2348–2360
Drasin DJ, Guarnieri AL, Neelakantan D et al (2015) TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res 75(9):1908–1921
Yi H, Liang B, Jia J et al (2013) Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett 587(5):436–443
Nygren MK, Tekle C, Ingebrigtsen VA et al (2014) Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer 110(8):2072–2080
Turchinovich A, Burwinkel B (2012) Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol 9(8):1066–1075
Turchinovich A, Weiz L, Langheinz A et al (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16):7223–7233
Pigati L, Yaddanapudi SC, Iyengar R et al (2010) Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5(10):e13515
Palma J, Yaddanapudi SC, Pigati L et al (2012) MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res 40(18):9125–9138
Eichelser C, Stuckrath I, Muller V et al (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5(20):9650–9663
Wang F, Zheng Z, Guo J et al (2010) Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 119(3):586–593
Girardi C, De Pitta C, Casara S et al (2014) Integration analysis of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in modeled microgravity. Biomed Res Int 2014:296747
Wang H, Tan G, Dong L et al (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7(4):e34210
Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I et al (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34(3):163–169
Madhavan D, Zucknick M, Wallwiener M et al (2012) Circulating microRNAs as surrogate markers for circulating tumour cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18(21):5972–5982
Liu J, Mao Q, Liu Y et al (2013) Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 25(1):46–54
Sochor M, Basova P, Pesta M et al (2014) Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 14:448
Shin VY, Siu JM, Cheuk I et al (2015) Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 112(11):1751–1759
Shen J, Hu Q, Schrauder M et al (2014) Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget 5(14):5284–5294
Chen D, Goswami CP, Burnett RM et al (2014) Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. Cancer Res 74(16):4270–4281
Schrauder MG, Strick R, Schulz-Wendtland R et al (2012) Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS One 7(1):e29770
Acknowledgments
This study was supported by the National High-Tech R&D Program of China (2012AA022501), the National Natural Science Foundation of China (81170097, 81373070), the National Natural Science Foundation of Jiangsu (BK2011381), and the 985 Project of Peking University.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
There are no conflicts of interest to disclose.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhang, L., Xu, Y., Jin, X. et al. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer. Breast Cancer Res Treat 154, 423–434 (2015). https://doi.org/10.1007/s10549-015-3591-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-015-3591-0